864829-41-4

Basic information

• Product Name: (-)-((7R,9S)-9-{[tert-butyl(dimethyl)silyl]oxy}-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-7-yl)methyl 4-methylbenzenesulfonate
• Synonyms: (-)-((7R,9S)-9-{[tert-butyl(dimethyl)silyl]oxy}-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-7-yl)methyl 4-methylbenzenesulfonate
• CAS NO: 864829-41-4
• Molecular Weight: 461.698
• Mol File: 864829-41-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (-)-((7R,9S)-9-{[tert-butyl(dimethyl)silyl]oxy}-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-7-yl)methyl 4-methylbenzenesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: (-)-((7R,9S)-9-{[tert-butyl(dimethyl)silyl]oxy}-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-7-yl)methyl 4-methylbenzenesulfonate(864829-41-4)
• EPA Substance Registry System: (-)-((7R,9S)-9-{[tert-butyl(dimethyl)silyl]oxy}-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-7-yl)methyl 4-methylbenzenesulfonate(864829-41-4)

Safety Data

• Hazardous Substances Data: 864829-41-4(Hazardous Substances Data)

Upstream product

• 28707-60-0 8-benzylidene-5,6,7,8-tetrahydroquinoline 
• 56826-69-8 5,6,7,8-tetrahydro-8-quinolinone 
• 10500-57-9 5,6,7,8-tetrahydroquinoline 
• 864499-16-1 ethyl 7-iodomethyl-8-oxo-5,6,7,8-tetrahydroquinoline-7-carboxylate 
• 864499-23-0 ethyl 9-oxo-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-7-carboxylate 
• 864499-10-5 ethyl 8-oxo-5,6,7,8-tetrahydroquinoline-7-carboxylate 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 864830-26-2 C₃₀H₄₆N₂O₂Si 

Relevant articles and documents

Practical syntheses of enantiomerically pure key intermediates of opioid receptor-like 1 (ORL1) antagonists

Practical syntheses of enantiomerically pure key intermediates of opioid receptor-like 1 (ORL1) antagonists are described. Our synthetic methodology features the preparation of multigram quantities of seven-membered key intermediate (-)-3 and six-membered one (-)-4 without the use of toxic tin reagents. In the case of (-)-3, the key step involved diastereoselective reduction using a sterically hindered reducing reagent. Our methodology allows for facile scale-up to afford the products in multigram quantities [in the case of (-)-4, >100-g quantities). These convenient approaches facilitate structure-activity relationship studies including in vivo cardiovascular adverse effects. Georg Thieme Verlag Stuttgart.

CYCLOALKANOPYRIDINE DERIVATIVE

Provided are cycloalkanopyridine derivatives of formula [I]: [wherein the symbols are the same as those stated in the description]. The compounds act as a nociceptin receptor antagonist, and are useful as medicines for diseases associated with a nociceptin receptor, for example, as a reliever against tolerance to a narcotic analgesic; a reliever against dependence on or addiction to a narcotic analgesic; an analgesic enhancer; an antiobesitic or appetite suppressor; a treating or prophylactic agent for cognitive impairment and dementia/amnesia; an agent for treating developmental cognitive abnormality; a remedy for schizophrenia; an agent for treating neurodegenerative diseases; an anti-depressant or treating agent for affective disorder; a treating or prophylactic agent for diabetes insipidus; a treating or prophylactic agent for polyuria; or a remedy for hypotension.